Search
forLearn
5 / 801 resultslearn Setipiprant
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn retinoic acid
learn Ciclopirox
Research
5 / 83 results
research Hair loss due to aripipirazole use: a case report
Stopping aripiprazole can reverse its side effect of hair loss.
research Psychopharmacological Treatment of Trichotillomania in an Adolescent Case: Significant Improvement with Aripiprazole Augmentation
Adding aripiprazole to the treatment improved hair-pulling symptoms in a teenager.
research Childhood onset trichotillomania: a retrospective analysis of 78 cases visiting tertiary general hospital
Children with trichotillomania often pull hair from their scalp and may have other mental health issues.
research Gilles de la Tourette syndrome – A treatable condition?
Gilles de la Tourette syndrome is treatable, with behavioral therapy as a recommended first option and other treatments available for more severe cases.
research Off Label Medication and Use of Unapproved Drugs
Off-label drug use can be risky but sometimes beneficial when standard treatments fail.
Community Join
5 / 1000+ resultscommunity I've been afflicted by post finasteride syndrome, what now?
A user experienced severe side effects from finasteride, including mental health issues and physical symptoms, and sought advice on managing post-finasteride syndrome. Suggestions included checking vitamin levels, considering dopamine agonists, and avoiding further psychiatric medications.
community Upcoming Setipiprant clinical trials hint at systemic daily dosage
The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.
community Pyrilutamide ,the molecule’s true nature
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
community Pyrilutamide Phase 3 on its way
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
community Setipiprant trial results
Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.